'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.

Metrion Biosciences provides GLP hERG testing services which crucial for drug discovery and the Investigational New Drug (IND) process. Our focus is on delivering reliable, regulatory-compliant data quickly and cost-effectively.

The hERG gene encodes a potassium ion channel that is essential for repolarizing the cardiac action potential. Inhibition of this channel can prolong the QT interval on an electrocardiogram (ECG), leading to a condition called Torsades de Pointes (TdP), a potentially fatal arrhythmia.

I am currently studying Biomedical Sciences at the University of Manchester. Through my previous years of education, I enjoyed studying biology and engaging in practical experiments, particularly those with clinical relevance, which ultimately guided my degree selection.

The recent ICH E14/S7B Q&As have provided more clarity on the methodologies that should be employed when conducting a GLP hERG to support and IND filing for a novel clinical compound.

My 12 month industrial placement at Metrion Biosciences was a truly remarkable experience that has helped me grow both personally and professionally. Choosing to complete a placement year was a big decision for me which was made 100% worth it!

Two-pore domain K+ (K2P) channels are a family of four-pass transmembrane K+ channels that dimerise, as homomers or heteromers, to form a functional K+ channel complex capable of regulating membrane potential through a background K+ conductance.

Kv3.1 is a voltage-gated potassium channel encoded by the KCNC1 gene. At the recent SLAS EU meeting, we presented a poster to demonstrate how a cell line expressing the KCNC1 V434L mutation was generated and validated using biophysical and pharmacological methods, then used to screen approximately 6,800 compounds from The Broad Institute Repurposing Hub to identify inhibitors for potential use in the treatment of patients with this rare mutation.